Editorial
doi: 10.1093/neuonc/nov018.
Epub 2015 Feb 13.
End of the road: confounding results of the CORE trial terminate the arduous journey of cilengitide for glioblastoma
Affiliations
- PMID: 25681307
- PMCID: PMC4482863
- DOI: 10.1093/neuonc/nov018
Item in Clipboard
Editorial
End of the road: confounding results of the CORE trial terminate the arduous journey of cilengitide for glioblastoma
Neuro Oncol.
2015 May.
No abstract available
Comment on
-
Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study.Neuro Oncol. 2015 May;17(5):708-17. doi: 10.1093/neuonc/nou356. Epub 2015 Mar 11. Neuro Oncol. 2015. PMID: 25762461 Free PMC article. Clinical Trial.
Similar articles
-
Cilengitide in glioblastoma: when did it fail?Lancet Oncol. 2014 Sep;15(10):1044-5. doi: 10.1016/S1470-2045(14)70403-6. Epub 2014 Aug 19. Lancet Oncol. 2014. PMID: 25163907 No abstract available.
-
Does cilengitide deserve another chance?Lancet Oncol. 2014 Dec;15(13):e584-e585. doi: 10.1016/S1470-2045(14)70462-0. Epub 2014 Nov 24. Lancet Oncol. 2014. PMID: 25456376 No abstract available.
-
Does cilengitide deserve another chance?-Authors' reply.Lancet Oncol. 2014 Dec;15(13):e585-e586. doi: 10.1016/S1470-2045(14)71121-0. Epub 2014 Nov 24. Lancet Oncol. 2014. PMID: 25456377 No abstract available.
-
[Strategy for studying gene methylation: the example of MGMT].Ann Pathol. 2009 Nov;29 Spec No 1:S37-9. doi: 10.1016/j.annpat.2009.07.015. Epub 2009 Oct 6. Ann Pathol. 2009. PMID: 19887248 Review. French. No abstract available.
-
Should biomarkers be used to design personalized medicine for the treatment of glioblastoma?Future Oncol. 2010 Sep;6(9):1407-14. doi: 10.2217/fon.10.113. Future Oncol. 2010. PMID: 20919826 Review.
Cited by
-
Treatment with αvβ3-integrin-specific 29P attenuates pressure-overload induced cardiac remodelling after transverse aortic constriction in mice.J Mol Cell Cardiol Plus. 2024 Jun;8:100069. doi: 10.1016/j.jmccpl.2024.100069. J Mol Cell Cardiol Plus. 2024. PMID: 38933087 Free PMC article.
-
Novel Pure αVβ3 Integrin Antagonists That Do Not Induce Receptor Extension, Prime the Receptor, or Enhance Angiogenesis at Low Concentrations.ACS Pharmacol Transl Sci. 2019 Aug 2;2(6):387-401. doi: 10.1021/acsptsci.9b00041. eCollection 2019 Dec 13. ACS Pharmacol Transl Sci. 2019. PMID: 32259072 Free PMC article.
-
Therapy-induced modulation of tumor vasculature and oxygenation in a murine glioblastoma model quantified by deep learning-based feature extraction.Sci Rep. 2024 Jan 23;14(1):2034. doi: 10.1038/s41598-024-52268-0. Sci Rep. 2024. PMID: 38263339 Free PMC article.
-
The functional role of integrins during intra- and extravasation within the metastatic cascade.Mol Cancer. 2019 Jan 18;18(1):12. doi: 10.1186/s12943-018-0937-3. Mol Cancer. 2019. PMID: 30657059 Free PMC article. Review.
-
Adaptive adhesion systems mediate glioma cell invasion in complex environments.J Cell Sci. 2018 Aug 13;131(15):jcs216382. doi: 10.1242/jcs.216382. J Cell Sci. 2018. PMID: 29991514 Free PMC article.
References
-
- Bello L, Francolini M, Marthyn P, et al. α(v)B3 and α(v)B5 integrin expression in glioma periphery. Neurosurgery. 2001;49(2):380–389. - PubMed
-
- Uhm JH, Dooley NP, Kyritsis AP, et al. Vitronectin, a glioma-derived extracellular matrix protein, protect tumor cells from apoptotic death. Clin Cancer Res. 1999;5(6):1587–1594. - PubMed
-
- Smith JW. Cilengitide Merck. Curr Opin Investig Drugs. 2003;4(6):741–745. - PubMed
-
- Yamada S, Bu XY, Khankaldyyan V, et al. Effect of the angiogenesis inhibitor cilengitide (EMD121974) on glioblastoma growth in nude mice. Neurosurgery. 2006;59(6):1304–1312. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
